top of page

$30M for Uncommon, the company redefining the future of meat

two women wearing yellow and blue clothing
Uncommon Co-Founders Dr. Ruth Faram and Benjamina Bollag

Imagine a world where you could still enjoy delicious, juicy, and tender bacon and pork belly, without compromising your health, harming the planet, or exploiting animals. Our latest investment, Uncommon, is at the forefront of this culinary revolution, leading the way in developing scalable cultivated meat.

We’re thrilled to take part in Uncommon’s (RAC VI) $30 million Series A funding round in collaboration with Balderton Capital, Lowercarbon Capital, East Alpha, and previous investors Max and Sam Altman, Miray Zaki and Sebastiano Castiglioni. Uncommon’s patent-pending RNA technology allows them to create cultivated bacon and pork belly from a single animal cell sample, enabling them to quickly achieve price parity with conventional meat and giving them an edge over competitors in the market.

Discussing our decision to invest, Michael Sidler, Partner at Redalpine, said: "Uncommon's completely novel approach holds immense potential to revolutionize the cultivated meat industry and overcome the notorious scalability and pricing obstacles that companies in this field face. What sets Uncommon apart is their ability to achieve this feat without using genetic modification, offering a smoother path through regulatory hurdles in Europe and further enhancing their position as true GameChangers in food production.”

The lab grown meat market is the holy grail of animal-free farming, valued at nearly $250M in 2022 and predicted to have a compound annual growth rate of 51.6% from 2023 to 2030. We’re convinced that Uncommon will dominate this market and beyond. Their initial focus on pork belly and bacon is just the beginning: In the future, they can apply their unique knowledge on pluripotent stem cells and RNA technologies to transform a host of other products.

Uncommon will use the funding to scale up production at their pilot manufacturing facility, initiate regulatory approval processes, and grow their team. 

We’re proud to support Uncommon in their goal to help the whole world experience the most innovative products that art and science can devise.

To learn more, visit Uncommon's new website or read this article on TechCrunch.


bottom of page